Catherine Magazu

Catherine Magazu

Catherine Magazu
+1 617 570 8274

Catherine Magazu is a Partner in the firm’s Life Sciences group. She joined Goodwin in 2014.

Catherine represents public and private companies in the pharmaceutical, biotechnology, and medical device industries. She advises clients in a variety of corporate matters, including start-up and formation matters, venture capital financings, initial public offerings, and capital markets transactions, strategic investments, and other general corporate matters.

While attending law school, Catherine was a member of the American Journal for Law & Medicine and received the Dean’s Award in Professional Responsibility.


  • Orchard Therapeutics in its $225.5 million initial public offering and initial U.S. listing, $128.3 million follow-on offering and its $150 million PIPE
  • Royalty Pharma in its acquisition of an interest in Ionis Pharmaceuticals’ royalty in Biogen’s SPINRAZA® (nusinersen) and Novartis’ pelacarsen for up to $1.12 billion, including an upfront payment of $500 million and up to $625 million in additional pelacarsen milestone payments
  • Royalty Pharma in its agreement with Merck to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being evaluated in a Phase 2b study for the treatment of schizophrenia
  • eGenesis in its $100 million Series B financing, $125 million Series C financing, and its acquisition of the assets and operations of ICBiotec 
  • Yumanity Therapeutics in more than $100 million in private equity financings, as well as debt financings, its merger with Proteostasis Therapeutics and concurrent PIPE, and its merger with Kineta
  • Delix Therapeutics on its $70 Million Series A financing 
  • AVROBIO in its seed financing with Atlas Ventures, $25 million and $60 million private financings, $115 million initial public offering and more than $200 million in follow-on public offerings
  • Regenacy Pharmaceuticals in its Series A and Series B financings
  • Zealand Pharma in the $205 million royalty and milestone monetization from Royalty Pharma of Zealand’s GLP-1 diabetes franchise
  • Barings in the purchase of certain rights from George Washington University related to the license by GWU of its vasoconstrictor drug to La Jolla Pharmaceutical Company
  • Onxeo in the $7.5 million royalty and milestone monetization from SWK Holdings of Onxeo’s oncology drug to treat refractory peripheral T cell lymphoma
  • Rodin Therapeutics in its private equity financings and $950 million sale to Alkermes 
  • Surface Oncology in its $108 million initial public offering and concurrent $11.5 million private placement
  • Acetylon Pharmaceuticals in its sale to Celgene Corporation and its spin-out of Regency Pharmaceuticals 
  • Dimension Therapeutics in its $72 million initial public offering
  • Allena Pharmaceuticals in its $53 million Series C financing 
  • Celyad S.A. in its $100.1 U.S. initial public offering




Boston University School of Law

(magna cum laude; G. Joseph Tauro Distinguished Scholar)


Smith College



  • Massachusetts

Recognition & Awards

Catherine has been recognized by The Best Lawyers in America Ones to Watch for her work in Technology Law 2022.